Thymoglobulin Injectable Product

DRUG2 trials

Sponsors

Nantes University Hospital, Institut Paoli-Calmettes

Conditions

Graft Versus Host DiseaseHematological Malignancy

Phase 2

Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC

TerminatedNCT03263767

Nantes University HospitalGraft Versus Host Disease

Start: 2018-01-15End: 2022-06-21Updated: 2022-07-15

PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM

Not yet recruitingNCT06066255

Institut Paoli-CalmettesHematological Malignancy

Start: 2024-03-31End: 2026-03-31Target: 27Updated: 2024-02-20

Related Papers

A Prospective Phase 2 Study Testing High Dose Post-Transplant Cyclophosphamide As Sole Ghvd Prophylaxis after Matched Allotransplant Using Baltimore-Based Reduced-Intensity Conditioning Regimens and PBSC As Source of Graft

Blood2021-11-051 citations